Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 177 entries
Sorted by: Best Match Show Resources per page
Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction.

European journal of heart failure

Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJ, Filippatos G, Greene SJ, McDonagh TA, Ponikowski P, Rosano G, Seferovic P, Vaduganathan M, Voors AA, Metra M.
PMID: 34894038
Eur J Heart Fail. 2021 Dec 10; doi: 10.1002/ejhf.2397. Epub 2021 Dec 10.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been recently recommended as a foundational therapy for patients with heart failure (HF) and reduced ejection fraction (HFrEF) because of their favourable effects on mortality, clinical events and quality of life. While clinical...

Cite
Tomasoni D, Fonarow GC, Adamo M, et al. Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2021;doi: 10.1002/ejhf.2397.
Tomasoni, D., Fonarow, G. C., Adamo, M., Anker, S. D., Butler, J., Coats, A. J., Filippatos, G., Greene, S. J., McDonagh, T. A., Ponikowski, P., Rosano, G., Seferovic, P., Vaduganathan, M., Voors, A. A., & Metra, M. (2021). Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction. European journal of heart failure, . https://doi.org/10.1002/ejhf.2397
Tomasoni, Daniela, et al. "Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction." European journal of heart failure vol. (2021). doi: https://doi.org/10.1002/ejhf.2397
Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJ, Filippatos G, Greene SJ, McDonagh TA, Ponikowski P, Rosano G, Seferovic P, Vaduganathan M, Voors AA, Metra M. Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2021 Dec 10; doi: 10.1002/ejhf.2397. Epub 2021 Dec 10. PMID: 34894038.
Copy Download .nbib Format: NLM
Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: Data from the AF-RISK study.

American heart journal

Artola Arita V, Santema BT, De With RR, Nguyen BO, Linz D, Schotten U, Van Gelder IC, Crijns HJ, Voors AA, Rienstra M.
PMID: 34688651
Am Heart J. 2021 Oct 21;244:36-41. doi: 10.1016/j.ahj.2021.10.183. Epub 2021 Oct 21.

Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are 2 cardiovascular conditions that often coexist. Strain phases of both the left and right atria are more impaired in paroxysmal AF patients with HFpEF than those without...

Cite
Artola Arita V, Santema BT, De With RR, et al. Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: Data from the AF-RISK study. Am Heart J. 2021;244:36-41doi: 10.1016/j.ahj.2021.10.183.
Artola Arita, V., Santema, B. T., De With, R. R., Nguyen, B. O., Linz, D., Schotten, U., Van Gelder, I. C., Crijns, H. J., Voors, A. A., & Rienstra, M. (2021). Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: Data from the AF-RISK study. American heart journal, 24436-41. https://doi.org/10.1016/j.ahj.2021.10.183
Artola Arita, Vicente, et al. "Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: Data from the AF-RISK study." American heart journal vol. 244 (2021): 36-41. doi: https://doi.org/10.1016/j.ahj.2021.10.183
Artola Arita V, Santema BT, De With RR, Nguyen BO, Linz D, Schotten U, Van Gelder IC, Crijns HJ, Voors AA, Rienstra M. Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: Data from the AF-RISK study. Am Heart J. 2021 Oct 21;244:36-41. doi: 10.1016/j.ahj.2021.10.183. Epub 2021 Oct 21. PMID: 34688651.
Copy Download .nbib Format: NLM
Drug development in oncology and devices-lessons for heart failure drug development and approval? a review.

Heart failure reviews

Davison BA, Cotter G, Filippatos GS, Zannad F, Voors AA, Metra M, Teerlink JR, Senger S, Mebazaa A, Greenberg B.
PMID: 32939666
Heart Fail Rev. 2021 Mar;26(2):255-262. doi: 10.1007/s10741-020-10020-6. Epub 2020 Sep 16.

Heart failure (HF) and cancer are of the most common diseases globally, both associated with significant adverse outcomes and greatly impaired quality of life. Despite those similarities, over the last 15 years, the United States (USA) and European authorities...

Cite
Davison BA, Cotter G, Filippatos GS, et al. Drug development in oncology and devices-lessons for heart failure drug development and approval? a review. Heart Fail Rev. 2020;26(2):255-262doi: 10.1007/s10741-020-10020-6.
Davison, B. A., Cotter, G., Filippatos, G. S., Zannad, F., Voors, A. A., Metra, M., Teerlink, J. R., Senger, S., Mebazaa, A., & Greenberg, B. (2021). Drug development in oncology and devices-lessons for heart failure drug development and approval? a review. Heart failure reviews, 26(2), 255-262. https://doi.org/10.1007/s10741-020-10020-6
Davison, Beth A, et al. "Drug development in oncology and devices-lessons for heart failure drug development and approval? a review." Heart failure reviews vol. 26,2 (2021): 255-262. doi: https://doi.org/10.1007/s10741-020-10020-6
Davison BA, Cotter G, Filippatos GS, Zannad F, Voors AA, Metra M, Teerlink JR, Senger S, Mebazaa A, Greenberg B. Drug development in oncology and devices-lessons for heart failure drug development and approval? a review. Heart Fail Rev. 2021 Mar;26(2):255-262. doi: 10.1007/s10741-020-10020-6. Epub 2020 Sep 16. PMID: 32939666.
Copy Download .nbib Format: NLM
Review of the environmental fate and effects of two UV filter substances used in cosmetic products.

The Science of the total environment

Duis K, Junker T, Coors A.
PMID: 34863752
Sci Total Environ. 2021 Dec 02;808:151931. doi: 10.1016/j.scitotenv.2021.151931. Epub 2021 Dec 02.

Sunscreens containing UV filters, such as octocrylene (OCR) and butyl-methoxydibenzoylmethane (BMDBM), have been increasingly used to protect human skin against UV radiation. Both substances have been detected in monitoring studies in the freshwater and marine environment, and there has...

Cite
Duis K, Junker T, Coors A. Review of the environmental fate and effects of two UV filter substances used in cosmetic products. Sci Total Environ. 2021;808:151931doi: 10.1016/j.scitotenv.2021.151931.
Duis, K., Junker, T., & Coors, A. (2021). Review of the environmental fate and effects of two UV filter substances used in cosmetic products. The Science of the total environment, 808151931. https://doi.org/10.1016/j.scitotenv.2021.151931
Duis, Karen, et al. "Review of the environmental fate and effects of two UV filter substances used in cosmetic products." The Science of the total environment vol. 808 (2021): 151931. doi: https://doi.org/10.1016/j.scitotenv.2021.151931
Duis K, Junker T, Coors A. Review of the environmental fate and effects of two UV filter substances used in cosmetic products. Sci Total Environ. 2021 Dec 02;808:151931. doi: 10.1016/j.scitotenv.2021.151931. Epub 2021 Dec 02. PMID: 34863752.
Copy Download .nbib Format: NLM
Cerebroprotective effects of angiotensin II (AT 1) receptor antagonists?.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation

Drenthen W, Voors AA, Kappelle JL, van Veldhuisen DJ.
PMID: 25696474
Neth Heart J. 2005 Apr;13(4):142-146.

The results of the Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) study show that treatment with an angiotensin receptor blocker (ARB) in the acute phase of a stroke improves mortality and cardiovascular morbidity. In addition, direct comparative antihypertensive...

Cite
Drenthen W, Voors AA, Kappelle JL, et al. Cerebroprotective effects of angiotensin II (AT 1) receptor antagonists?. Neth Heart J. 2005;13(4):142-146
Drenthen, W., Voors, A. A., Kappelle, J. L., & van Veldhuisen, D. J. (2005). Cerebroprotective effects of angiotensin II (AT 1) receptor antagonists?. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 13(4), 142-146.
Drenthen, W, et al. "Cerebroprotective effects of angiotensin II (AT 1) receptor antagonists?." Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation vol. 13,4 (2005): 142-146.
Drenthen W, Voors AA, Kappelle JL, van Veldhuisen DJ. Cerebroprotective effects of angiotensin II (AT 1) receptor antagonists?. Neth Heart J. 2005 Apr;13(4):142-146. PMID: 25696474; PMCID: PMC2497294.
Copy Download .nbib Format: NLM
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.

Revista espanola de cardiologia (English ed.)

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P.
PMID: 27894487
Rev Esp Cardiol (Engl Ed). 2016 Dec;69(12):1167. doi: 10.1016/j.rec.2016.11.005.

No abstract available.

Cite
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Rev Esp Cardiol (Engl Ed). 2016;69(12):1167doi: 10.1016/j.rec.2016.11.005.
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V. P., Jankowska, E. A., Jessup, M., Linde, C., Nihoyannopoulos, P., Parissis, J. T., Pieske, B., Riley, J. P., Rosano, G. M. C., Ruilope, L. M., Ruschitzka, F., Rutten, F. H., & van der Meer, P. (2016). 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Revista espanola de cardiologia (English ed.), 69(12), 1167. https://doi.org/10.1016/j.rec.2016.11.005
Ponikowski, Piotr, et al. "2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure." Revista espanola de cardiologia (English ed.) vol. 69,12 (2016): 1167. doi: https://doi.org/10.1016/j.rec.2016.11.005
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Rev Esp Cardiol (Engl Ed). 2016 Dec;69(12):1167. doi: 10.1016/j.rec.2016.11.005. Spanish. PMID: 27894487.
Copy Download .nbib Format: NLM
The role of action potential changes in depolarization-induced failure of excitation contraction coupling in mouse skeletal muscle.

eLife

Wang X, Nawaz M, DuPont C, Myers JH, Burke SR, Bannister R, Foy BD, Voss AA, Rich MM.
PMID: 34985413
Elife. 2022 Jan 05;11. doi: 10.7554/eLife.71588.

Excitation-contraction coupling (ECC) is the process by which electrical excitation of muscle is converted into force generation. Depolarization of skeletal muscle resting potential contributes to failure of ECC in diseases such as periodic paralysis, intensive care unit acquired weakness...

Cite
Wang X, Nawaz M, DuPont C, et al. The role of action potential changes in depolarization-induced failure of excitation contraction coupling in mouse skeletal muscle. Elife. 2022;11doi: 10.7554/eLife.71588.
Wang, X., Nawaz, M., DuPont, C., Myers, J. H., Burke, S. R., Bannister, R., Foy, B. D., Voss, A. A., & Rich, M. M. (2022). The role of action potential changes in depolarization-induced failure of excitation contraction coupling in mouse skeletal muscle. eLife, 11. https://doi.org/10.7554/eLife.71588
Wang, Xueyong, et al. "The role of action potential changes in depolarization-induced failure of excitation contraction coupling in mouse skeletal muscle." eLife vol. 11 (2022). doi: https://doi.org/10.7554/eLife.71588
Wang X, Nawaz M, DuPont C, Myers JH, Burke SR, Bannister R, Foy BD, Voss AA, Rich MM. The role of action potential changes in depolarization-induced failure of excitation contraction coupling in mouse skeletal muscle. Elife. 2022 Jan 05;11. doi: 10.7554/eLife.71588. PMID: 34985413.
Copy Download .nbib Format: NLM
Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: Data from the AF-RISK study.

American heart journal

Artola Arita V, Santema BT, De With RR, Nguyen BO, Linz D, Schotten U, Van Gelder IC, Crijns HJ, Voors AA, Rienstra M.
PMID: 34688651
Am Heart J. 2021 Oct 21;244:36-41. doi: 10.1016/j.ahj.2021.10.183. Epub 2021 Oct 21.

Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are 2 cardiovascular conditions that often coexist. Strain phases of both the left and right atria are more impaired in paroxysmal AF patients with HFpEF than those without...

Cite
Artola Arita V, Santema BT, De With RR, et al. Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: Data from the AF-RISK study. Am Heart J. 2021;244:36-41doi: 10.1016/j.ahj.2021.10.183.
Artola Arita, V., Santema, B. T., De With, R. R., Nguyen, B. O., Linz, D., Schotten, U., Van Gelder, I. C., Crijns, H. J., Voors, A. A., & Rienstra, M. (2021). Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: Data from the AF-RISK study. American heart journal, 24436-41. https://doi.org/10.1016/j.ahj.2021.10.183
Artola Arita, Vicente, et al. "Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: Data from the AF-RISK study." American heart journal vol. 244 (2021): 36-41. doi: https://doi.org/10.1016/j.ahj.2021.10.183
Artola Arita V, Santema BT, De With RR, Nguyen BO, Linz D, Schotten U, Van Gelder IC, Crijns HJ, Voors AA, Rienstra M. Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: Data from the AF-RISK study. Am Heart J. 2021 Oct 21;244:36-41. doi: 10.1016/j.ahj.2021.10.183. Epub 2021 Oct 21. PMID: 34688651.
Copy Download .nbib Format: NLM
Trace formula for noise corrections to trace formulas.

Physical review. E, Statistical, nonlinear, and soft matter physics

Palla G, Vattay G, Voros A.
PMID: 11461305
Phys Rev E Stat Nonlin Soft Matter Phys. 2001 Jul;64(1):012104. doi: 10.1103/PhysRevE.64.012104. Epub 2001 Jun 15.

We consider an evolution operator for a discrete Langevin equation with a strongly hyperbolic classical dynamics and Gaussian noise. Using an integral representation of the evolution operator L, we investigate the high-order corrections to the trace of L(n). The...

Cite
Palla G, Vattay G, Voros A. Trace formula for noise corrections to trace formulas. Phys Rev E Stat Nonlin Soft Matter Phys. 2001;64(1):012104doi: 10.1103/PhysRevE.64.012104.
Palla, G., Vattay, G., & Voros, A. (2001). Trace formula for noise corrections to trace formulas. Physical review. E, Statistical, nonlinear, and soft matter physics, 64(1), 012104. https://doi.org/10.1103/PhysRevE.64.012104
Palla, G, et al. "Trace formula for noise corrections to trace formulas." Physical review. E, Statistical, nonlinear, and soft matter physics vol. 64,1 (2001): 012104. doi: https://doi.org/10.1103/PhysRevE.64.012104
Palla G, Vattay G, Voros A. Trace formula for noise corrections to trace formulas. Phys Rev E Stat Nonlin Soft Matter Phys. 2001 Jul;64(1):012104. doi: 10.1103/PhysRevE.64.012104. Epub 2001 Jun 15. PMID: 11461305.
Copy Download .nbib Format: NLM
Anatomy of the trace formula for the baker's map.

Chaos (Woodbury, N.Y.)

Saraceno M, Voros A.
PMID: 12779956
Chaos. 1992 Jan;2(1):99-103. doi: 10.1063/1.165922.

The structure of the trace formula for quantum maps on a compact phase space is analyzed. An explicit expression for the functional determinant in terms of a finite number of traces is derived which is algebraic and independent of...

Cite
Saraceno M, Voros A. Anatomy of the trace formula for the baker's map. Chaos. 1992;2(1):99-103doi: 10.1063/1.165922.
Saraceno, M., & Voros, A. (1992). Anatomy of the trace formula for the baker's map. Chaos (Woodbury, N.Y.), 2(1), 99-103. https://doi.org/10.1063/1.165922
Saraceno, M., and Voros, A.. "Anatomy of the trace formula for the baker's map." Chaos (Woodbury, N.Y.) vol. 2,1 (1992): 99-103. doi: https://doi.org/10.1063/1.165922
Saraceno M, Voros A. Anatomy of the trace formula for the baker's map. Chaos. 1992 Jan;2(1):99-103. doi: 10.1063/1.165922. PMID: 12779956.
Copy Download .nbib Format: NLM
Publisher Correction: Time dependent decomposition of ammonia borane for the controlled production of 2D hexagonal boron nitride.

Scientific reports

Babenko V, Lane G, Koos AA, Murdock AT, So K, Britton J, Meysami SS, Moffat J, Grobert N.
PMID: 29167581
Sci Rep. 2017 Nov 22;7(1):16346. doi: 10.1038/s41598-017-16514-y.

A correction to this article has been published and is linked from the HTML version of this paper. The error has been fixed in the paper.

Cite
Babenko V, Lane G, Koos AA, et al. Publisher Correction: Time dependent decomposition of ammonia borane for the controlled production of 2D hexagonal boron nitride. Sci Rep. 2017;7(1):16346doi: 10.1038/s41598-017-16514-y.
Babenko, V., Lane, G., Koos, A. A., Murdock, A. T., So, K., Britton, J., Meysami, S. S., Moffat, J., & Grobert, N. (2017). Publisher Correction: Time dependent decomposition of ammonia borane for the controlled production of 2D hexagonal boron nitride. Scientific reports, 7(1), 16346. https://doi.org/10.1038/s41598-017-16514-y
Babenko, Vitaliy, et al. "Publisher Correction: Time dependent decomposition of ammonia borane for the controlled production of 2D hexagonal boron nitride." Scientific reports vol. 7,1 (2017): 16346. doi: https://doi.org/10.1038/s41598-017-16514-y
Babenko V, Lane G, Koos AA, Murdock AT, So K, Britton J, Meysami SS, Moffat J, Grobert N. Publisher Correction: Time dependent decomposition of ammonia borane for the controlled production of 2D hexagonal boron nitride. Sci Rep. 2017 Nov 22;7(1):16346. doi: 10.1038/s41598-017-16514-y. PMID: 29167581; PMCID: PMC5700194.
Copy Download .nbib Format: NLM
Prognostic Factors in Typical and Atypical Pulmonary Carcinoids.

The Ochsner journal

Ramirez RA, Beyer DT, Diebold AE, Voros BA, Chester MM, Wang YZ, Boudreaux JP, Woltering EA, Uhlhorn AP, Ryan P, Campeau RJ, Anthony LB.
PMID: 29230118
Ochsner J. 2017;17(4):335-340.

BACKGROUND: Typical and atypical carcinoids represent approximately 2% of all lung tumors. Survival of patients with typical bronchial carcinoids, unlike the survival of patients with most lung tumors, is generally long but dependent on stage. We report the findings...

Cite
Ramirez RA, Beyer DT, Diebold AE, et al. Prognostic Factors in Typical and Atypical Pulmonary Carcinoids. Ochsner J. 2017;17(4):335-340
Ramirez, R. A., Beyer, D. T., Diebold, A. E., Voros, B. A., Chester, M. M., Wang, Y. Z., Boudreaux, J. P., Woltering, E. A., Uhlhorn, A. P., Ryan, P., Campeau, R. J., & Anthony, L. B. (2017). Prognostic Factors in Typical and Atypical Pulmonary Carcinoids. The Ochsner journal, 17(4), 335-340.
Ramirez, Robert A, et al. "Prognostic Factors in Typical and Atypical Pulmonary Carcinoids." The Ochsner journal vol. 17,4 (2017): 335-340.
Ramirez RA, Beyer DT, Diebold AE, Voros BA, Chester MM, Wang YZ, Boudreaux JP, Woltering EA, Uhlhorn AP, Ryan P, Campeau RJ, Anthony LB. Prognostic Factors in Typical and Atypical Pulmonary Carcinoids. Ochsner J. 2017;17(4):335-340. PMID: 29230118; PMCID: PMC5718446.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 177 entries